Is NSP a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Benefits pricing versus claim cost trend, with revenue (ttm) at ~$6.9 billion (Q2 2026 ~$1.69 billion, up ~2% year over year). The bear case rests on the central risk is health-care cost inflation. Analysts covering it are spread from $38.00 to $61.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The central risk is health-care cost inflation. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $38.00, -29.2% from the $53.67 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Benefits pricing versus claim cost trend. Insperity's profit is mostly the gap between what it charges clients for health coverage and what the plan pays out. The most optimistic analyst target on NSP is $61.00, +13.7% from the $53.67 price. That figure is only reachable if this thesis works close to its best case.

The central risk is health-care cost inflation. Insperity effectively underwrites the medical costs of its clients' employees, so a rise in large claims, GLP-1 and specialty drug utilization, or hospital pricing can erase a year of margin in a single quarter, as Q4 2025 showed. Pricing up to recover that margin risks driving away the healthiest, most price-sensitive clients, leaving a worse risk pool behind (adverse selection). Unit growth is negative, and a slowdown in small-business hiring or a recession would shrink WSEE counts further. HRScale may take longer to sell than planned, and Workday could favor other partners or build its own services, leaving Insperity with sunk costs. Competition is intense from TriNet, ADP TotalSource and Paychex on price, and from software platforms like Rippling and Gusto that offer cheaper PEO-lite bundles. The balance sheet is tighter than it was, with ~$420 million of credit facility borrowings and a dividend that is larger than current GAAP earnings, so a cut is plausible if recovery stalls. Guidance ranges are unusually wide (Q3 adjusted EPS of ~-$0.09 to ~$0.41), which reflects real uncertainty, and the stock has more than doubled from its March low, so expectations into the October 29 report are higher than they were. The most pessimistic published target is $38.00, -29.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

One of the largest US professional employer organizations, handling payroll, benefits and HR for small and midsize businesses.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Benefits pricing versus claim cost trend) stalling in the reported numbers rather than in the narrative, the risk above (the central risk is health-care cost inflation) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

NSP rose ~7% intraday on October 22, 2026, reaching ~$53.70 and approaching its 52-week high of ~$55.90. We found no merger announcement, SEC filing, guidance change or analyst action tied to the move. The likeliest explanations are positioning ahead of the Q3 2026 report on October 29, when investors will see whether margin recovery held through the summer, and continued interest following the October 15 launch of an HR360 AI agent. The stock also carries a relatively small float of ~38 million shares, so moves can be sharp. It is worth noting the context: shares have nearly tripled from the ~$18.57 March 2026 low as the company returned to profit, so the October 22 gain extends a large recovery rally rather than starting a new story.

Insperity is a professional employer organization. A client business, typically with 5 to 5,000 employees, signs a co-employment agreement under which Insperity becomes the employer of record for payroll, tax filing, workers' compensation and employee benefits, while the client keeps directing daily work. Because Insperity pools ~306,000 worksite employees across thousands of clients, it can offer large-company health plans through UnitedHealthcare, 401(k) plans and HR expertise that a small firm could not buy alone. It also sells HR360, its HR platform with an AI agent added in October 2026, and since February 2026 HRScale, a combined offering with Workday software aimed at larger midsized companies. Insperity is headquartered in Kingwood, Texas, and is listed on the NYSE under NSP.

The core problem was benefits costs. Insperity prices its health coverage a year ahead, and in 2025 claims came in far higher than that pricing assumed, driven by more frequent large claims, specialty pharmacy (including GLP-1 drugs) and outpatient trends. Gross profit fell ~14% for the year to ~$900 million and ~21% in Q4 alone. At the same time, the company was spending ~$48 million on its Workday partnership. The combination produced a ~$33 million Q4 net loss and a full-year GAAP loss of ~$7 million, versus solid profits a year earlier. Adjusted EPS fell to ~$1.03. The share price, which had traded above $100 in 2024, dropped to ~$18.57 by March 2026 as investors questioned how quickly margins could recover.